title,type,agency_names,abstract,citation,document_number,html_url,pdf_url,publication_date,Title Product,Title Note,Assignment,Product Name,Patent No.,Company,Reg Rev Period,Testing Phase,Approval Phase,IND/IDE Filing Date,NDA/PMA Filing Date,Approval Date,Application No.,Pat Term Ext
Determination of Regulatory Review Period for Purposes of Patent Extension; VIBERZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIBERZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5105,2018-02187,https://www.federalregister.gov/documents/2018/02/05/2018-02187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viberzi,https://www.govinfo.gov/content/pkg/FR-2018-02-05/pdf/2018-02187.pdf,2018-02-05, VIBERZI,,Nicolas,VIBERZI,7741356; 8344011; and 8609709,"Janssen Pharmaceutica, N.V.",2716.0,2381,335.0,2007-12-21,2014-06-27,2015-05-27,NDA 206940,431
Determination of Regulatory Review Period for Purposes of Patent Extension; FARXIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FARXIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5436,2018-02418,https://www.federalregister.gov/documents/2018/02/07/2018-02418/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farxiga,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02418.pdf,2018-02-07, FARXIGA,,Nicolas,FARXIGA,6414126 and 6515117,AstraZeneca AB,3673.0,2565,1108.0,2003-12-21,2003-12-21,2014-01-08,NDA 202293,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2018-02-07, BLINCYTO,,Nicolas,BLINCYTO,7112324 and 8007796,Amgen Research (Munich) GMBH,2850.0,2774,76.0,2007-02-15,2007-02-15,2014-12-03,BLA 125557,432
Determination of Regulatory Review Period for Purposes of Patent Extension; GENVOYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GENVOYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5431,2018-02403,https://www.federalregister.gov/documents/2018/02/07/2018-02403/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genvoya,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02403.pdf,2018-02-07, GENVOYA,,Nicolas,GENVOYA,7390791 and 7803788,"Gilead Sciences, Inc.",5031.0,4665,366.0,2002-01-28,2002-01-28,2015-11-05,NDA 207561,1116
Determination of Regulatory Review Period for Purposes of Patent Extension; SEDASYS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for SEDASYS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 5429,2018-02432,https://www.federalregister.gov/documents/2018/02/07/2018-02432/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sedasys-system,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02432.pdf,2018-02-07, SEDASYS SYSTEM,,Nicolas,SEDASYS SYSTEM,6807965,"Scott Laboratories, Inc.",2816.0,950,1866.0,2005-08-19,2005-08-19,2013-05-03,PMA P080009,2283
Determination of Regulatory Review Period for Purposes of Patent Extension; JUBLIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JUBLIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5633,2018-02522,https://www.federalregister.gov/documents/2018/02/08/2018-02522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jublia,https://www.govinfo.gov/content/pkg/FR-2018-02-08/pdf/2018-02522.pdf,2018-02-08, JUBLIA,,Nicolas,JUBLIA,7214506,"Kaken Pharmaceutical Co., Ltd.",2521.0,1840,681.0,2007-07-14,2007-07-14,2014-06-06,NDA 203567,1601
Determination of Regulatory Review Period for Purposes of Patent Extension; STRENSIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STRENSIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5776,2018-02588,https://www.federalregister.gov/documents/2018/02/09/2018-02588/determination-of-regulatory-review-period-for-purposes-of-patent-extension-strensiq,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02588.pdf,2018-02-09, STRENSIQ,,Nicolas,STRENSIQ,7763712,"Alexion Pharmaceuticals, Inc.",2670.0,2365,305.0,2008-07-03,2008-07-03,2015-10-23,BLA 125513,1109
Determination of Regulatory Review Period for Purposes of Patent Extension; ODOMZO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ODOMZO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5780,2018-02658,https://www.federalregister.gov/documents/2018/02/09/2018-02658/determination-of-regulatory-review-period-for-purposes-of-patent-extension-odomzo,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02658.pdf,2018-02-09, ODOMZO,,Nicolas,ODOMZO,8178563,Novartis AG,2414.0,2112,302.0,2008-12-15,2014-09-26,2015-07-24,NDA 205266,169
Determination of Regulatory Review Period for Purposes of Patent Extension; IDELVION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IDELVION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5787,2018-02666,https://www.federalregister.gov/documents/2018/02/09/2018-02666/determination-of-regulatory-review-period-for-purposes-of-patent-extension-idelvion,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02666.pdf,2018-02-09, IDELVION,,Nicolas,IDELVION,7939632,CSL Behring GmbH,1479.0,1023,456.0,2012-02-17,2012-02-17,2016-03-04,BLA 125582,531
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2018-02-09, LYNPARZA,,Nicolas,LYNPARZA,7449464,Kudos Pharmaceuticals Limited,3012.0,2692,320.0,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275
Determination of Regulatory Review Period for Purposes of Patent Extension; ONIVYDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ONIVYDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5790,2018-02590,https://www.federalregister.gov/documents/2018/02/09/2018-02590/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onivyde,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02590.pdf,2018-02-09, ONIVYDE,,Nicolas,ONIVYDE,8147867 and 8329213,"Merrimack Pharmaceuticals, Inc.",2536.0,2354,182.0,2008-11-13,2015-04-24,2015-10-22,NDA 207793,1215
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTRESTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENTRESTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5781,2018-02592,https://www.federalregister.gov/documents/2018/02/09/2018-02592/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entresto,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02592.pdf,2018-02-09, ENTRESTO,,Nicolas,ENTRESTO,7468390; 8101659; 8404744; 8796331; and 8877938,Novartis Pharmaceuticals Corporation,3148.0,2945,203.0,2006-11-25,2014-12-17,2015-07-07,NDA 207620,225
Determination of Regulatory Review Period for Purposes of Patent Extension; KAMRA INLAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KAMRA INLAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 5778,2018-02582,https://www.federalregister.gov/documents/2018/02/09/2018-02582/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kamra-inlay,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02582.pdf,2018-02-09, KAMRA INLAY,,Nicolas,KAMRA INLAY,8460374,"AcuFocus, Inc.",2347.0,1541,806.0,2016-07-12,2008-11-14,2015-04-17,PMA P120023,676
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2018-02-12, IMBRUVICA,,Nicolas,IMBRUVICA,8008309,"Pharmacyclics, Inc.",1865.0,1726,139.0,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320
Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DALVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6031,2018-02768,https://www.federalregister.gov/documents/2018/02/12/2018-02768/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dalvance,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02768.pdf,2018-02-12, DALVANCE,,Nicolas,DALVANCE,6900175,"Vicuron Pharmaceuticals, Inc.",5033.0,1592,3441.0,2000-08-13,2000-08-13,2014-05-23,NDA 21883,1612
Determination of Regulatory Review Period for Purposes of Patent Extension; BELSOMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BELSOMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6034,2018-02763,https://www.federalregister.gov/documents/2018/02/12/2018-02763/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belsomra,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02763.pdf,2018-02-12, BELSOMRA,,Nicolas,BELSOMRA,7951797,Merck Sharp & Dohme Corp.,2291.0,1577,714.0,2008-05-07,2008-05-07,2014-08-13,NDA 204569,0
Determination of Regulatory Review Period for Purposes of Patent Extension; AKYNZEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AKYNZEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6038,2018-02756,https://www.federalregister.gov/documents/2018/02/12/2018-02756/determination-of-regulatory-review-period-for-purposes-of-patent-extension-akynzeo,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02756.pdf,2018-02-12, AKYNZEO,,Nicolas,AKYNZEO,6297375,Hoffmann-La Roche Inc.,1858.0,1479,379.0,2009-09-10,2013-09-27,2014-10-10,NDA 205718,1118
Determination of Regulatory Review Period for Purposes of Patent Extension; GILOTRIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GILOTRIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6026,2018-02767,https://www.federalregister.gov/documents/2018/02/12/2018-02767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilotrif,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02767.pdf,2018-02-12, GILOTRIF,,Nicolas,GILOTRIF,RE43431,"Boehringer Ingelheim Pharma Gmbh & Co., KG",3453.0,3213,240.0,2004-01-30,2012-11-15,2013-07-12,NDA 201292,1057
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRAVECTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 6033,2018-02761,https://www.federalregister.gov/documents/2018/02/12/2018-02761/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02761.pdf,2018-02-12, BRAVECTO,,Nicolas,BRAVECTO,7662972,"Nissan Chemical Industries, Ltd.",1017.0,979,38.0,2011-08-04,2014-04-08,2014-05-15,NADA 141-426,792
Determination of Regulatory Review Period for Purposes of Patent Extension; VASCEPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VASCEPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6192,2018-02851,https://www.federalregister.gov/documents/2018/02/13/2018-02851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vascepa,https://www.govinfo.gov/content/pkg/FR-2018-02-13/pdf/2018-02851.pdf,2018-02-13, VASCEPA,,Nicolas,VASCEPA,8188146,Amarin Pharmaceuticals Ireland Limited,1133.0,828,305.0,2009-06-21,2009-06-21,2012-07-26,NDA 202057,58
Determination of Regulatory Review Period for Purposes of Patent Extension; FARYDAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FARYDAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6198,2018-02868,https://www.federalregister.gov/documents/2018/02/13/2018-02868/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farydak,https://www.govinfo.gov/content/pkg/FR-2018-02-13/pdf/2018-02868.pdf,2018-02-13, FARYDAK,,Nicolas,FARYDAK,6552065; 6833384; and 7067551,Novartis AG,4334.0,3997,337.0,2003-04-15,2003-04-15,2015-02-23,NDA 205353,1751
Determination of Regulatory Review Period for Purposes of Patent Extension; BELEODAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BELEODAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6576,2018-03041,https://www.federalregister.gov/documents/2018/02/14/2018-03041/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beleodaq,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03041.pdf,2018-02-14, BELEODAQ,,Nicolas,BELEODAQ,6888027,"Spectrum Pharmaceuticals, Inc.",3488.0,3281,207.0,2004-12-16,2013-12-09,2014-07-03,NDA 206256,1779
Determination of Regulatory Review Period for Purposes of Patent Extension; IBRANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IBRANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6581,2018-03029,https://www.federalregister.gov/documents/2018/02/14/2018-03029/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibrance,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03029.pdf,2018-02-14, IBRANCE,,Nicolas,IBRANCE,6936612 and 7208489,"Warner-Lambert Company, LLC",3954.0,3779,175.0,2004-04-09,2014-08-13,2015-02-03,NDA 207103,1509
Determination of Regulatory Review Period for Purposes of Patent Extension; JARDIANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for JARDIANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6583,2018-02992,https://www.federalregister.gov/documents/2018/02/14/2018-02992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jardiance,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02992.pdf,2018-02-14, JARDIANCE,,Nicolas,JARDIANCE,7579449,Boehringer Ingelheim International GmbH,2275.0,1760,515.0,2008-05-11,2008-05-11,2014-08-01,NDA 204629,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; KERYDIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KERYDIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6579,2018-02993,https://www.federalregister.gov/documents/2018/02/14/2018-02993/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kerydin,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02993.pdf,2018-02-14, KERYDIN,,Nicolas,KERYDIN,7582621,"Anacor Pharmaceuticals, Inc.",3112.0,2768,344.0,2005-12-31,2013-07-29,2014-07-07,NDA 204427,408
Determination of Regulatory Review Period for Purposes of Patent Extension; OSURNIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OSURNIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 6577,2018-02991,https://www.federalregister.gov/documents/2018/02/14/2018-02991/determination-of-regulatory-review-period-for-purposes-of-patent-extension-osurnia,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02991.pdf,2018-02-14, OSURNIA,,Nicolas,OSURNIA,7854943,IDEXX,4034.0,3980,54.0,2003-10-21,2014-11-04,2014-11-04,NADA 141-,235
Determination of Regulatory Review Period for Purposes of Patent Extension; JUVEDERM VOLUMA XC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JUVEDERM VOLUMA XC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 6574,2018-03017,https://www.federalregister.gov/documents/2018/02/14/2018-03017/determination-of-regulatory-review-period-for-purposes-of-patent-extension-juvederm-voluma-xc,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03017.pdf,2018-02-14, JUVEDERM VOLUMA XC,,Nicolas,JUVEDERM VOLUMA XC,7741476,Pierre Lebreton,1896.0,1110,786.0,2015-10-30,2015-10-30,2013-10-22,PMA P110033,567
Determination of Regulatory Review Period for Purposes of Patent Extension; SYLVANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYLVANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 6866,2018-03126,https://www.federalregister.gov/documents/2018/02/15/2018-03126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sylvant,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03126.pdf,2018-02-15, SYLVANT,,Nicolas,SYLVANT,7612182 and 7291721,"Janssen Biotech, Inc.",3747.0,3510,237.0,2004-01-21,2004-01-21,2014-04-23,BLA 125496,1300
Determination of Regulatory Review Period for Purposes of Patent Extension; AVEED,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVEED and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6858,2018-03136,https://www.federalregister.gov/documents/2018/02/15/2018-03136/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aveed,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03136.pdf,2018-02-15, AVEED,,Nicolas,AVEED,8338395,Bayer Intellectual Property GmbH,2923.0,541,2382.0,2006-03-06,2006-03-06,2014-03-05,NDA 022219,435
Determination of Regulatory Review Period for Purposes of Patent Extension; FETZIMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FETZIMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6859,2018-03129,https://www.federalregister.gov/documents/2018/02/15/2018-03129/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fetzima,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03129.pdf,2018-02-15, FETZIMA,,Nicolas,FETZIMA,RE43879,Pierre Fabre Medicament,1602.0,1298,304.0,2009-03-08,2012-09-25,2013-07-25,NDA 204168,954
Determination of Regulatory Review Period for Purposes of Patent Extension; ZONTIVITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZONTIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6864,2018-03170,https://www.federalregister.gov/documents/2018/02/15/2018-03170/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zontivity,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03170.pdf,2018-02-15, ZONTIVITY,,Nicolas,ZONTIVITY,7304078,Merck Sharp & Dohme Corp.,3401.0,3037,364.0,2005-01-16,2013-05-10,2014-05-08,NDA 204886,1357
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIDION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIDION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6856,2018-03137,https://www.federalregister.gov/documents/2018/02/15/2018-03137/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bridion,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03137.pdf,2018-02-15, BRIDION,,Nicolas,BRIDION,RE44733,"Merck Sharp & Dohme, B.V.",4265.0,1297,2968.0,2004-04-13,2004-04-13,2015-12-15,NDA 022225,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ORKAMBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORKAMBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6868,2018-03127,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03127.pdf,2018-02-15, ORKAMBI,,Nicolas,ORKAMBI,8653103; 8741933; and 8846718,Vertex Pharmaceuticals Inc.,2785.0,2545,240.0,2007-11-18,2014-11-05,2015-07-02,NDA 206038,317
Determination of Regulatory Review Period for Purposes of Patent Extension; ADDYI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADDYI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6855,2018-03130,https://www.federalregister.gov/documents/2018/02/15/2018-03130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-addyi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03130.pdf,2018-02-15, ADDYI,,Nicolas,ADDYI,7151103 and 7420057,"Sprout Pharmaceuticals, Inc.",6852.0,4730,2122.0,1996-11-15,2009-10-27,2015-08-18,NDA 22-526,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYDELIG-New Drug Application 205858,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYDELIG based on new drug application (NDA) 205858 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product and that NDA.",83 FR 6861,2018-03134,https://www.federalregister.gov/documents/2018/02/15/2018-03134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03134.pdf,2018-02-15, ZYDELIG-New Drug Application 205858,,Nicolas,ZYDELIG,RE44599 and RE44638,ICOS Corporation,2247.0,1931,316.0,2008-05-30,2018-04-16,2014-07-23,NDA 205858,751
Determination of Regulatory Review Period for Purposes of Patent Extension; HYMOVIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYMOVIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 7059,2018-03229,https://www.federalregister.gov/documents/2018/02/16/2018-03229/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hymovis,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03229.pdf,2018-02-16, HYMOVIS,,Nicolas,HYMOVIS,7863256,Fidia Farmaceutici S.p.A.,1845.0,1665,180.0,2010-08-11,2010-08-11,2015-08-28,PMA P150010,938
Determination of Regulatory Review Period for Purposes of Patent Extension; COTELLIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for COTELLIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7054,2018-03218,https://www.federalregister.gov/documents/2018/02/16/2018-03218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cotellic,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03218.pdf,2018-02-16, COTELLIC,,Nicolas,COTELLIC,7803839 and 8362002,"Exelixis, Inc.",3219.0,2884,335.0,2007-01-19,2014-12-11,2015-11-10,NDA 206192,676
Determination of Regulatory Review Period for Purposes of Patent Extension; MOVANTIK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOVANTIK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7042,2018-03245,https://www.federalregister.gov/documents/2018/02/16/2018-03245/determination-of-regulatory-review-period-for-purposes-of-patent-extension-movantik,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03245.pdf,2018-02-16, MOVANTIK,,Nicolas,MOVANTIK,7662365 and 7786133,Nektar Therapeutics,2493.0,2127,366.0,2007-11-21,2007-11-21,2014-09-16,NDA 204760,272
Determination of Regulatory Review Period for Purposes of Patent Extension; PORTRAZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PORTRAZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7191,2018-03345,https://www.federalregister.gov/documents/2018/02/20/2018-03345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-portrazza,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03345.pdf,2018-02-20, PORTRAZZA,,Nicolas,PORTRAZZA,7598350,Eli Lilly,2533.0,2175,358.0,2008-12-19,2008-12-19,2015-11-24,BLA 125547,1321
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2018-02-20, DARZALEX,,Nicolas,DARZALEX,7829673,Genmab A/S,1939.0,1808,131.0,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000
Determination of Regulatory Review Period for Purposes of Patent Extension; MAESTRO RECHARGEABLE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAESTRO RECHARGEABLE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 7196,2018-03343,https://www.federalregister.gov/documents/2018/02/20/2018-03343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maestro-rechargeable,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03343.pdf,2018-02-20, MAESTRO RECHARGEABLE SYSTEM,,Nicolas,MAESTRO RECHARGEABLE SYSTEM,7672727,EnteroMedics Inc.,2866.0,2296,570.0,2007-03-13,2007-03-13,2015-01-14,PMA P130019,385
Determination of Regulatory Review Period for Purposes of Patent Extension; LYMPHOSEEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYMPHOSEEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7734,2018-03610,https://www.federalregister.gov/documents/2018/02/22/2018-03610/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lymphoseek,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03610.pdf,2018-02-22, LYMPHOSEEK,,Nicolas,LYMPHOSEEK,6409990,"Navidea Biopharmaceuticals, Inc.",4398.0,3816,582.0,2001-02-28,2001-02-28,2013-03-13,NDA 202207,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; OFEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OFEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7747,2018-03606,https://www.federalregister.gov/documents/2018/02/22/2018-03606/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ofev,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03606.pdf,2018-02-22, OFEV,,Nicolas,OFEV,6762180,Boehringer Ingelheim Pharma Gmbh & Co. KG,3480.0,3313,167.0,2005-04-07,2005-04-07,2014-10-15,NDA 205832,1822
Determination of Regulatory Review Period for Purposes of Patent Extension; ESBRIET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ESBRIET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7732,2018-03612,https://www.federalregister.gov/documents/2018/02/22/2018-03612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-esbriet,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03612.pdf,2018-02-22, ESBRIET,,Nicolas,ESBRIET,7767225; 7767700; 7988994; 8383150; and 8420674,InterMune Inc.,14993.0,13186,1807.0,1973-09-29,1973-09-29,2014-10-15,NDA 22-535,754
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYDELIG-New Drug Application 206545,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYDELIG based on new drug application (NDA) 206545 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 8088,2018-03701,https://www.federalregister.gov/documents/2018/02/23/2018-03701/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-02-23/pdf/2018-03701.pdf,2018-02-23, ZYDELIG-New Drug Application 206545,,Nicolas,ZYDELIG,RE44599 and RE44638,ICOS Corporation,2247.0,2017,230.0,2008-05-30,2018-04-24,2014-07-23,NDA 206545,708
Determination of Regulatory Review Period for Purposes of Patent Extension; TREMFYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TREMFYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52471,2018-22571,https://www.federalregister.gov/documents/2018/10/17/2018-22571/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tremfya,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22571.pdf,2018-10-17, TREMFYA,,Nicolas,TREMFYA,and 7993645,"Janssen Biotech, Inc.",2968.0,2728,240.0,2009-05-30,2009-05-30,2017-07-13,BLA 761061,1203
Determination of Regulatory Review Period for Purposes of Patent Extension; DUPIXENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DUPIXENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52481,2018-22566,https://www.federalregister.gov/documents/2018/10/17/2018-22566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dupixent,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22566.pdf,2018-10-17, DUPIXENT,,Nicolas,DUPIXENT,7608693,"Regeneron Pharmaceuticals, Inc.",2728.0,2485,243.0,2009-10-10,2009-10-10,2017-03-28,BLA 761055,1273
Determination of Regulatory Review Period for Purposes of Patent Extension; BRINEURA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINEURA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52483,2018-22559,https://www.federalregister.gov/documents/2018/10/17/2018-22559/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brineura,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22559.pdf,2018-10-17, BRINEURA,,Nicolas,BRINEURA,8029781,"Rutgers, the State University of New Jersey",995.0,659,336.0,2014-08-08,2014-08-08,2017-04-27,BLA 761052,666
Determination of Regulatory Review Period for Purposes of Patent Extension; OCREVUS,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA or the Agency) has,83 FR 52837,2018-22699,https://www.federalregister.gov/documents/2018/10/18/2018-22699/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocrevus,https://www.govinfo.gov/content/pkg/FR-2018-10-18/pdf/2018-22699.pdf,2018-10-18, OCREVUS,,Nicolas,OCREVUS,7799900 and 8562992,"Genentech, Inc.",4844.0,4509,335.0,2003-12-25,2003-12-25,2017-03-28,BLA 761053,795
Determination of Regulatory Review Period for Purposes of Patent Extension; AFSTYLA,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA or the Agency) has,83 FR 52839,2018-22696,https://www.federalregister.gov/documents/2018/10/18/2018-22696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afstyla,https://www.govinfo.gov/content/pkg/FR-2018-10-18/pdf/2018-22696.pdf,2018-10-18, AFSTYLA,,Nicolas,AFSTYLA,7041635,"SK Chemicals Co, LTD.",1734.0,1371,363.0,2011-08-28,2011-08-28,2016-05-25,BLA 125591,1047
Determination of Regulatory Review Period for Purposes of Patent Extension; IMFINZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMFINZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53067,2018-22806,https://www.federalregister.gov/documents/2018/10/19/2018-22806/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imfinzi,https://www.govinfo.gov/content/pkg/FR-2018-10-19/pdf/2018-22806.pdf,2018-10-19, IMFINZI,,Nicolas,IMFINZI,8779108 and 9493565,MedImmune Limited,1755.0,1554,201.0,2012-07-13,2012-07-13,2017-05-01,BLA 761069,159
Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TYMLOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 53260,2018-22956,https://www.federalregister.gov/documents/2018/10/22/2018-22956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tymlos,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22956.pdf,2018-10-22, TYMLOS,,Nicolas,TYMLOS,7803770; 8148333; and 8748382,"Radius Health, Inc.",4130.0,3735,395.0,2006-01-08,2006-01-08,2017-04-28,NDA 208743,1128
Determination of Regulatory Review Period for Purposes of Patent Extension; BESPONSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BESPONSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53273,2018-22958,https://www.federalregister.gov/documents/2018/10/22/2018-22958/determination-of-regulatory-review-period-for-purposes-of-patent-extension-besponsa,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22958.pdf,2018-10-22, BESPONSA,,Nicolas,BESPONSA,8153768; 8835611; and 8747857,Wyeth Holdings LLC,5298.0,5057,241.0,2003-02-16,2003-02-16,2017-08-17,BLA 761040,1099
Determination of Regulatory Review Period for Purposes of Patent Extension; TECENTRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECENTRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53259,2018-22957,https://www.federalregister.gov/documents/2018/10/22/2018-22957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecentriq,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22957.pdf,2018-10-22, TECENTRIQ,,Nicolas,TECENTRIQ,8217149,"Genentech, Inc.",1836.0,1708,128.0,2011-05-11,2011-05-11,2016-05-18,BLA 761034,769
Determination of Regulatory Review Period for Purposes of Patent Extension; NUPLAZID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NUPLAZID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 53481,2018-23057,https://www.federalregister.gov/documents/2018/10/23/2018-23057/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuplazid,https://www.govinfo.gov/content/pkg/FR-2018-10-23/pdf/2018-23057.pdf,2018-10-23, NUPLAZID,,Nicolas,NUPLAZID,7601740; 7659285; and 7732615,ACADIA Pharmaceuticals Inc.,4557.0,4315,242.0,2003-11-09,2003-11-09,2016-04-29,NDA 207-318,1316
Determination of Regulatory Review Period for Purposes of Patent Extension; SILIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SILIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53476,2018-23058,https://www.federalregister.gov/documents/2018/10/23/2018-23058/determination-of-regulatory-review-period-for-purposes-of-patent-extension-siliq,https://www.govinfo.gov/content/pkg/FR-2018-10-23/pdf/2018-23058.pdf,2018-10-23, SILIQ,,Nicolas,SILIQ,7767206; 7939070; 8435518; and 8545842,"Kirin-Amgen, Inc.",3101.0,2643,458.0,2008-08-22,2008-08-22,2017-02-15,BLA 761032,847
Determination of Regulatory Review Period for Purposes of Patent Extension; LARTRUVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LARTRUVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53640,2018-23219,https://www.federalregister.gov/documents/2018/10/24/2018-23219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lartruvo,https://www.govinfo.gov/content/pkg/FR-2018-10-24/pdf/2018-23219.pdf,2018-10-24, LARTRUVO,,Nicolas,LARTRUVO,8128929,Imclone LLC,3766.0,3527,239.0,2006-06-30,2006-06-30,2016-10-19,BLA 761038,1003
Determination of Regulatory Review Period for Purposes of Patent Extension; TALTZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALTZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 54108,2018-23438,https://www.federalregister.gov/documents/2018/10/26/2018-23438/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taltz,https://www.govinfo.gov/content/pkg/FR-2018-10-26/pdf/2018-23438.pdf,2018-10-26, TALTZ,,Nicolas,TALTZ,7838638 and 8110191,Eli Lilly,3036.0,2670,366.0,2007-12-01,2007-12-01,2016-03-22,BLA 125521,935
Determination of Regulatory Review Period for Purposes of Patent Extension; REBINYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBINYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 54112,2018-23437,https://www.federalregister.gov/documents/2018/10/26/2018-23437/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rebinyn,https://www.govinfo.gov/content/pkg/FR-2018-10-26/pdf/2018-23437.pdf,2018-10-26, REBINYN,,Nicolas,REBINYN,7138371 and 7179617,Novo Nordisk A/S,2793.0,2412,381.0,2009-10-09,2009-10-09,2017-05-31,BLA 125611,1660
Determination of Regulatory Review Period for Purposes of Patent Extension; RAINDROP NEAR VISION INLAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAINDROP NEAR VISION INLAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 54360,2018-23527,https://www.federalregister.gov/documents/2018/10/29/2018-23527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raindrop-near-vision,https://www.govinfo.gov/content/pkg/FR-2018-10-29/pdf/2018-23527.pdf,2018-10-29, RAINDROP NEAR VISION INLAY,,Nicolas,RAINDROP NEAR VISION INLAY,8057541,"ReVision Optics, Inc.",2354.0,2074,280.0,2017-09-20,2010-01-20,2016-06-29,PMA P150034,828
Determination of Regulatory Review Period for Purposes of Patent Extension; KEVZARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEVZARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 61643,2018-26033,https://www.federalregister.gov/documents/2018/11/30/2018-26033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kevzara,https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26033.pdf,2018-11-30, KEVZARA,,Nicolas,KEVZARA,7582298 and 8568721,"Regeneron Pharmaceuticals, Inc.",3478.0,2907,571.0,2007-11-15,2007-11-15,2017-05-22,BLA 761037,937
Determination of Regulatory Review Period for Purposes of Patent Extension; PROVAYBLUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PROVAYBLUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 61645,2018-26035,https://www.federalregister.gov/documents/2018/11/30/2018-26035/determination-of-regulatory-review-period-for-purposes-of-patent-extension-provayblue,https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26035.pdf,2018-11-30, PROVAYBLUE,,Nicolas,PROVAYBLUE,8765942,Provepharm S.A.S.,415.0,232,183.0,2015-02-20,2015-02-20,2016-04-08,NDA 204630,298
Determination of Regulatory Review Period for Purposes of Patent Extension; TRULANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRULANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 62590,2018-26289,https://www.federalregister.gov/documents/2018/12/04/2018-26289/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulance,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26289.pdf,2018-12-04, TRULANCE,,Nicolas,TRULANCE,7041786,"Synergy Pharmaceuticals, Inc.",3186.0,2829,357.0,2008-05-02,2008-05-02,2017-01-19,NDA 208745,1771
Determination of Regulatory Review Period for Purposes of Patent Extension; OCALIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OCALIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 62591,2018-26288,https://www.federalregister.gov/documents/2018/12/04/2018-26288/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocaliva,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26288.pdf,2018-12-04, OCALIVA,,Nicolas,OCALIVA,7138390,"Intercept Pharmaceuticals, Inc.",3742.0,3408,334.0,2006-03-01,2006-03-01,2016-05-27,NDA 207999,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ASPIRE ASSIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ASPIRE ASSIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 62580,2018-26290,https://www.federalregister.gov/documents/2018/12/04/2018-26290/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aspire-assist,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26290.pdf,2018-12-04, ASPIRE ASSIST,,Nicolas,ASPIRE ASSIST,9039677,"Aspire Bariatrics, Inc.",2785.0,2444,341.0,2008-10-31,2008-10-31,2016-06-14,PMA P150024,385
Determination of Regulatory Review Period for Purposes of Patent Extension; EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM (EXABLATE) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 62593,2018-26282,https://www.federalregister.gov/documents/2018/12/04/2018-26282/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exablate-neuro-model-4000,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26282.pdf,2018-12-04, EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM,,Nicolas,EXABLATE,6612988,Brigham,2050.0,1785,265.0,2019-02-04,2010-12-02,2016-07-11,PMA P150038,1158
Determination of Regulatory Review Period for Purposes of Patent Extension; ABSORB GT1 BIORESORBABLE SCAFFOLD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ABSORB GT1 Bioresorbable Scaffold and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 65680,2018-27678,https://www.federalregister.gov/documents/2018/12/21/2018-27678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-absorb-gt1-bioresorbable,https://www.govinfo.gov/content/pkg/FR-2018-12-21/pdf/2018-27678.pdf,2018-12-21, ABSORB GT1 BIORESORBABLE SCAFFOLD,,Nicolas,ABSORB GT1 BIORESORBABLE SCAFFOLD,7971333 and 8323329,Abbott Cardiovascular Systems Inc.,1303.0,932,371.0,2012-12-12,2012-12-12,2016-07-05,PMA P150023,841
Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for ADLYXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 66279,2018-27805,https://www.federalregister.gov/documents/2018/12/26/2018-27805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adlyxin,https://www.govinfo.gov/content/pkg/FR-2018-12-26/pdf/2018-27805.pdf,2018-12-26, ADLYXIN,,Nicolas,ADLYXIN,RE45313,ZP Holding SPV K/S,5500.0,5133,367.0,2001-07-08,2001-07-08,2016-07-27,NDA 208471,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PARSABIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67293,2018-28221,https://www.federalregister.gov/documents/2018/12/28/2018-28221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-parsabiv,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28221.pdf,2018-12-28, PARSABIV,,Nicolas,PARSABIV,8377880; 8999932; and 9278995,"KAI Pharmaceuticals, Inc.",2335.0,1801,534.0,2010-09-19,2010-09-19,2017-02-07,NDA 208325,193
Determination of Regulatory Review Period for Purposes of Patent Extension; XERMELO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XERMELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67296,2018-28218,https://www.federalregister.gov/documents/2018/12/28/2018-28218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xermelo,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28218.pdf,2018-12-28, XERMELO,,Nicolas,XERMELO,7709493,"Lexicon Pharmaceuticals, Inc.",3329.0,2993,336.0,2008-01-20,2008-01-20,2017-02-28,NDA 208794,1175
Determination of Regulatory Review Period for Purposes of Patent Extension; RUBRACA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUBRACA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67290,2018-28217,https://www.federalregister.gov/documents/2018/12/28/2018-28217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rubraca,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28217.pdf,2018-12-28, RUBRACA,,Nicolas,RUBRACA,6495541,"Agouron Pharmaceuticals, LLC",2644.0,2464,180.0,2009-09-25,2009-09-25,2016-12-19,NDA 209115,1412
Determination of Regulatory Review Period for Purposes of Patent Extension; RYDAPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYDAPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67295,2018-28216,https://www.federalregister.gov/documents/2018/12/28/2018-28216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rydapt,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28216.pdf,2018-12-28, RYDAPT,,Nicolas,RYDAPT,7973031; 8222244; and 8575146,Novartis AG,6737.0,6494,243.0,1998-11-19,1998-11-19,2017-04-28,NDA 207997,1183
Determination of Regulatory Review Period for Purposes of Patent Extension; EXONDYS 51,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXONDYS 51 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3186,2019-01851,https://www.federalregister.gov/documents/2019/02/11/2019-01851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exondys-51,https://www.govinfo.gov/content/pkg/FR-2019-02-11/pdf/2019-01851.pdf,2019-02-11, EXONDYS 51,,Nicolas,EXONDYS 51,7807816 and 9018368,the University of Western Australia,2280.0,1828,452.0,2015-09-18,2010-06-25,2016-09-19,NDA 206488,481
Determination of Regulatory Review Period for Purposes of Patent Extension; EUCRISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EUCRISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",84 FR 3458,2019-01956,https://www.federalregister.gov/documents/2019/02/12/2019-01956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eucrisa,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-01956.pdf,2019-02-12, EUCRISA,,Nicolas,EUCRISA,8039451 and 8168614,"Anacor Pharmaceuticals, Inc.",3121.0,2778,343.0,2008-05-31,2008-05-31,2016-12-14,NDA 207695,1114
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEJULA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEJULA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3470,2019-02036,https://www.federalregister.gov/documents/2019/02/12/2019-02036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zejula,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02036.pdf,2019-02-12, ZEJULA,,Nicolas,ZEJULA,8071623,MSD Italia S.R.l.,3234.0,3086,148.0,2008-05-21,2008-05-21,2017-03-27,NDA 208447,370
Determination of Regulatory Review Period for Purposes of Patent Extension; XADAGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XADAGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3456,2019-02044,https://www.federalregister.gov/documents/2019/02/12/2019-02044/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xadago,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02044.pdf,2019-02-12, XADAGO,,Nicolas,XADAGO,8076515 and 8283380,Newron Pharmaceuticals S.p.A.,5019.0,4205,814.0,2003-06-26,2003-06-26,2017-03-21,NDA 207145,831
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMPROIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMPROIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 15226,2019-07459,https://www.federalregister.gov/documents/2019/04/15/2019-07459/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symproic,https://www.govinfo.gov/content/pkg/FR-2019-04-15/pdf/2019-07459.pdf,2019-04-15, SYMPROIC,,Nicolas,SYMPROIC,RE46365,"Shionogi & Co., Ltd.",2523.0,2157,366.0,2010-04-28,2010-04-28,2017-03-23,NDA 208854,1140
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,2019-04-29, YESCARTA,,Nicolas,YESCARTA,7741465,Cabaret Biotech Ltd.,3243.0,3041,202.0,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498
Determination of Regulatory Review Period for Purposes of Patent Extension; AUSTEDO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AUSTEDO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 20896,2019-09805,https://www.federalregister.gov/documents/2019/05/13/2019-09805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-austedo,https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09805.pdf,2019-05-13, AUSTEDO,,Nicolas,AUSTEDO,8524733,"Auspex Pharmaceuticals, Inc.",1736.0,1060,676.0,2012-07-03,2012-07-03,2017-04-03,NDA 208082,8
Determination of Regulatory Review Period for Purposes of Patent Extension; GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 20894,2019-09817,https://www.federalregister.gov/documents/2019/05/13/2019-09817/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gore-viabahn-vbx-balloon,https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09817.pdf,2019-05-13, GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,,Nicolas,the GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,6461665,"W.L. Gore & Associates, Inc.",1136.0,931,205.0,2013-12-20,2013-12-20,2017-01-27,PMA P160021,669
Determination of Regulatory Review Period for Purposes of Patent Extension; EDWARDS INTUITY ELITE AORTIC VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EDWARDS INTUITY ELITE AORTIC VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 24158,2019-10889,https://www.federalregister.gov/documents/2019/05/24/2019-10889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edwards-intuity-elite,https://www.govinfo.gov/content/pkg/FR-2019-05-24/pdf/2019-10889.pdf,2019-05-24, EDWARDS INTUITY ELITE AORTIC VALVE,,Nicolas,EDWARDS INTUITY ELITE AORTIC VALVE,8911493,Edwards Lifesciences Corp.,1508.0,1203,305.0,2012-06-28,2012-06-28,2016-08-12,PMA P150036,605
Determination of Regulatory Review Period for Purposes of Patent Extension; ALUNBRIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALUNBRIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27137,2019-12320,https://www.federalregister.gov/documents/2019/06/11/2019-12320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alunbrig,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12320.pdf,2019-06-11, ALUNBRIG,,Nicolas,ALUNBRIG,9012462,"ARIAD Pharmaceutials, Inc.",2105.0,1862,243.0,2011-07-26,2011-07-26,2017-04-28,NDA 208772,81
Determination of Regulatory Review Period for Purposes of Patent Extension; KISQALI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KISQALI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",84 FR 27128,2019-12305,https://www.federalregister.gov/documents/2019/06/11/2019-12305/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kisqali,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12305.pdf,2019-06-11, KISQALI,,Nicolas,KISQALI,8324225; 8415355; 8685980; 8962630; and 9416136,Novartis AG,2393.0,2196,197.0,2010-08-26,2010-08-26,2017-03-13,NDA 209092,204
Determination of Regulatory Review Period for Purposes of Patent Extension; BAXDELA TABLETS-NDA 208610,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAXDELA TABLETS under NDA 208610 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27133,2019-12299,https://www.federalregister.gov/documents/2019/06/11/2019-12299/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-tablets-nda,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12299.pdf,2019-06-11, BAXDELA TABLETS-NDA 208610,,Nicolas,BAXDELA,7728143 and 8252813,"Melinta Therapeutics, Inc.",5813.0,5569,244.0,2001-07-22,2001-07-22,2017-06-19,NDA 208610,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; BAXDELA IV INJECTION-NDA 208611,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAXDELA IV INJECTION under new drug application (NDA) 208611 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27126,2019-12298,https://www.federalregister.gov/documents/2019/06/11/2019-12298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-iv-injection-nda,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12298.pdf,2019-06-11, BAXDELA IV INJECTION-NDA 208611,,Nicolas,BAXDELA,7728143 and 8252813,"Melinta Therapeutics, Inc.",5813.0,5569,244.0,2001-07-22,2019-08-12,2017-06-19,NDA 208611,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; NERLYNX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NERLYNX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 45769,2019-18816,https://www.federalregister.gov/documents/2019/08/30/2019-18816/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nerlynx,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18816.pdf,2019-08-30, NERLYNX,,Nicolas,NERLYNX,7399865 and 9211291,"Puma Biotechnology, Inc.",5102.0,4738,364.0,2003-07-31,2003-07-31,2017-07-17,NDA 208051,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; MACI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MACI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 45776,2019-18805,https://www.federalregister.gov/documents/2019/08/30/2019-18805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maci,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18805.pdf,2019-08-30, MACI,,Nicolas,MACI,8029992,Vericel Corporation,345.0,0,345.0,2016-01-04,2016-01-04,2016-12-13,BLA 125603,345
Determination of Regulatory Review Period for Purposes of Patent Extension; BEVYXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEVYXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 45778,2019-18788,https://www.federalregister.gov/documents/2019/08/30/2019-18788/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bevyxxa,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18788.pdf,2019-08-30, BEVYXXA,,Nicolas,BEVYXXA,6376515; 6835739; 7598276; and 8518977,"Millennium Pharmaceuticals, Inc.",4244.0,4001,243.0,2005-11-11,2005-11-11,2017-06-23,NDA 208383,821
Determination of Regulatory Review Period for Purposes of Patent Extension; GIAPREZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GIAPREZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 46740,2019-19110,https://www.federalregister.gov/documents/2019/09/05/2019-19110/determination-of-regulatory-review-period-for-purposes-of-patent-extension-giapreza,https://www.govinfo.gov/content/pkg/FR-2019-09-05/pdf/2019-19110.pdf,2019-09-05, GIAPREZA,,Nicolas,GIAPREZA,9572856,George Washington University,1639.0,1463,176.0,2013-06-28,2013-06-28,2017-12-21,NDA 209360,241
Determination of Regulatory Review Period for Purposes of Patent Extension; SHINGRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SHINGRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 46953,2019-19205,https://www.federalregister.gov/documents/2019/09/06/2019-19205/determination-of-regulatory-review-period-for-purposes-of-patent-extension-shingrix,https://www.govinfo.gov/content/pkg/FR-2019-09-06/pdf/2019-19205.pdf,2019-09-06, SHINGRIX,,Nicolas,SHINGRIX,7939084,GlaxoSmithKline Biologicals SA,3257.0,2892,365.0,2008-11-21,2008-11-21,2017-10-20,BLA 125614,1361
Determination of Regulatory Review Period for Purposes of Patent Extension; AEGEA VAPOR SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AEGEA VAPOR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 47520,2019-19496,https://www.federalregister.gov/documents/2019/09/10/2019-19496/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aegea-vapor-system,https://www.govinfo.gov/content/pkg/FR-2019-09-10/pdf/2019-19496.pdf,2019-09-10, AEGEA VAPOR SYSTEM,,Nicolas,AEGEA VAPOR SYSTEM,8574226,"Tsunami MedTech, LLC",1381.0,1148,233.0,2013-09-04,2013-09-04,2017-06-14,PMA P160047,931
Determination of Regulatory Review Period for Purposes of Patent Extension; Edwards Pericardial Aortic Bioprosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS (Models 11000A and 11500A) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 47960,2019-19600,https://www.federalregister.gov/documents/2019/09/11/2019-19600/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edwards-pericardial,https://www.govinfo.gov/content/pkg/FR-2019-09-11/pdf/2019-19600.pdf,2019-09-11, Edwards Pericardial Aortic Bioprosthesis,,Nicolas,EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS MODEL 11000A and MODEL 11500A,7972376; 8007992; 8357387; and 9029418,Edwards Lifesciences Corporation,1858.0,1491,367.0,2012-05-30,2012-05-30,2017-06-29,PMA P150048,1111
Determination of Regulatory Review Period for Purposes of Patent Extension; Med-El Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MED-EL Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System (MED-EL EAS) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 50042,2019-20657,https://www.federalregister.gov/documents/2019/09/24/2019-20657/determination-of-regulatory-review-period-for-purposes-of-patent-extension-med-el-electric-and,https://www.govinfo.gov/content/pkg/FR-2019-09-24/pdf/2019-20657.pdf,2019-09-24, Med-El Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System,,Nicolas,MED-EL EAS,7917224,Med-El Electromedizinische Gerate GmbH,4537.0,4269,268.0,2004-04-16,2004-04-16,2016-09-15,PMA P000025,998
Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRYSVITA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",84 FR 65823,2019-25821,https://www.federalregister.gov/documents/2019/11/29/2019-25821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crysvita,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25821.pdf,2019-11-29, CRYSVITA,,Nicolas,CRYSVITA,7314618; 7883705; and 9290569,Indiana University Research,3485.0,3241,244.0,2008-10-03,2008-10-03,2018-04-17,BLA 761068,"5 days, 1,168 days, or 501 days"
Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OZEMPIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 65826,2019-25850,https://www.federalregister.gov/documents/2019/11/29/2019-25850/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ozempic,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25850.pdf,2019-11-29, OZEMPIC,,Nicolas,OZEMPIC,8129343,Novo Nordisk A/S,3336.0,2970,366.0,2008-10-19,2008-10-19,2017-12-05,NDA 209637,1040
Determination of Regulatory Review Period for Purposes of Patent Extension; AIMOVIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AIMOVIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66201,2019-26081,https://www.federalregister.gov/documents/2019/12/03/2019-26081/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aimovig,https://www.govinfo.gov/content/pkg/FR-2019-12-03/pdf/2019-26081.pdf,2019-12-03, AIMOVIG,,Nicolas,AIMOVIG,9102731,"Amgen, Inc.",2042.0,1675,367.0,2012-10-16,2012-10-16,2018-05-17,BLA 761077,689
Determination of Regulatory Review Period for Purposes of Patent Extension; LUXTURNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUXTURNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66682,2019-26252,https://www.federalregister.gov/documents/2019/12/05/2019-26252/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luxturna,https://www.govinfo.gov/content/pkg/FR-2019-12-05/pdf/2019-26252.pdf,2019-12-05, LUXTURNA,,Nicolas,LUXTURNA,9433688,"Trustees of the University of Pennsylvania, the University of Florida Research Foundation, Inc.",3809.0,3591,218.0,2007-07-18,2007-07-18,2017-12-19,BLA 125610,344
Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANDEXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",84 FR 66671,2019-26251,https://www.federalregister.gov/documents/2019/12/05/2019-26251/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andexxa,https://www.govinfo.gov/content/pkg/FR-2019-12-05/pdf/2019-26251.pdf,2019-12-05, ANDEXXA,,Nicolas,ANDEXXA,8153590; 8889129; and 9388401,"Portola Pharmaceuticals, Inc.",2171.0,1302,869.0,2012-05-25,2012-05-25,2018-05-03,BLA 125586,1066
Determination of Regulatory Review Period for Purposes of Patent Extension; PALYNZIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PALYNZIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66916,2019-26327,https://www.federalregister.gov/documents/2019/12/06/2019-26327/determination-of-regulatory-review-period-for-purposes-of-patent-extension-palynziq,https://www.govinfo.gov/content/pkg/FR-2019-12-06/pdf/2019-26327.pdf,2019-12-06, PALYNZIQ,,Nicolas,PALYNZIQ,7534595 and 7537923,Biomarin Pharmaceutical Inc.,3803.0,3474,329.0,2007-12-27,2007-12-27,2018-05-24,BLA B761079,1743
Determination of Regulatory Review Period for Purposes of Patent Extension; VABOMERE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VABOMERE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67746,2019-26655,https://www.federalregister.gov/documents/2019/12/11/2019-26655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vabomere,https://www.govinfo.gov/content/pkg/FR-2019-12-11/pdf/2019-26655.pdf,2019-12-11, VABOMERE,,Nicolas,VABOMERE,8680136,"Rempex Pharmaceuticals, Inc.",1316.0,1072,244.0,2014-01-23,2014-01-23,2017-08-29,NDA 209776,12
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT INJECTION New Drug Application 205837,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67945,2019-26812,https://www.federalregister.gov/documents/2019/12/12/2019-26812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-injection-new,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26812.pdf,2019-12-12, BRIVIACT INJECTION New Drug Application 205837,,Nicolas,BRIVIACT INJECTION,6784197,UCB Biopharma SPRL,4293.0,3753,540.0,2004-08-12,2017-01-18,2016-02-18,NDA 205837,1547
"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL TABLETS, New Drug Application 205836",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT ORAL TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67947,2019-26813,https://www.federalregister.gov/documents/2019/12/12/2019-26813/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-oral-tablets-new,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26813.pdf,2019-12-12," BRIVIACT ORAL TABLETS, New Drug Application 205836",,Nicolas,BRIVIACT ORAL TABLETS,6911461,UCB Biopharma SPRL,4293.0,3753,540.0,2004-08-12,2017-01-18,2016-02-18,NDA 205836,5
"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL SOLUTION, New Drug Application 205838",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT ORAL SOLUTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67942,2019-26814,https://www.federalregister.gov/documents/2019/12/12/2019-26814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-oral-solution,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26814.pdf,2019-12-12," BRIVIACT ORAL SOLUTION, New Drug Application 205838",,Nicolas,BRIVIACT ORAL SOLUTION,8492416,UCB Biopharma SPRL,4293.0,3753,540.0,2004-08-12,2017-01-18,2016-02-18,NDA 205836,698
Determination of Regulatory Review Period for Purposes of Patent Extension; MAVYRET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAVYRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",85 FR 3694,2020-00936,https://www.federalregister.gov/documents/2020/01/22/2020-00936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mavyret,https://www.govinfo.gov/content/pkg/FR-2020-01-22/pdf/2020-00936.pdf,2020-01-22, MAVYRET,,Nicolas,MAVYRET,8937150 and 9586978,"AbbVie, Inc.",1725.0,1492,233.0,2012-11-14,2012-11-12,2017-08-03,NDA 209394,150
Determination of Regulatory Review Period for Purposes of Patent Extension; INTRAROSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INTRAROSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 8879,2020-03115,https://www.federalregister.gov/documents/2020/02/18/2020-03115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intrarosa,https://www.govinfo.gov/content/pkg/FR-2020-02-18/pdf/2020-03115.pdf,2020-02-18, INTRAROSA,,Nicolas,INTRAROSA,8629129 and 8957054,"Endorecherche, Inc.",3381.0,2983,398.0,2007-08-17,2007-08-17,2016-11-16,NDA 208470,518
Determination of Regulatory Review Period for Purposes of Patent Extension; ILUMYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ILUMYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 12565,2020-04362,https://www.federalregister.gov/documents/2020/03/03/2020-04362/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilumya,https://www.govinfo.gov/content/pkg/FR-2020-03-03/pdf/2020-04362.pdf,2020-03-03, ILUMYA,,Nicolas,ILUMYA,8293883 and 8404813,Merck Sharp & Dohme Corp.,3452.0,3089,363.0,2008-10-08,2008-10-08,2018-03-20,BLA 761067,1092
Determination of Regulatory Review Period for Purposes of Patent Extension; FASENRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FASENRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 12793,2020-04363,https://www.federalregister.gov/documents/2020/03/04/2020-04363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fasenra,https://www.govinfo.gov/content/pkg/FR-2020-03-04/pdf/2020-04363.pdf,2020-03-04, FASENRA,,Nicolas,FASENRA,7179464; 7718175; and 8101185,"Kyowa Hakko Kirin Co., Ltd.",4127.0,3763,364.0,2006-07-30,2006-07-30,2017-11-14,BLA 761070,1244
Determination of Regulatory Review Period for Purposes of Patent Extension; INGREZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INGREZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 12928,2020-04545,https://www.federalregister.gov/documents/2020/03/05/2020-04545/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ingrezza,https://www.govinfo.gov/content/pkg/FR-2020-03-05/pdf/2020-04545.pdf,2020-03-05, INGREZZA,,Nicolas,INGREZZA,8039627,"Neurocrine Biosciences, Inc.",2071.0,1827,244.0,2011-08-12,2011-08-12,2017-04-11,NDA 209241,552
Determination of Regulatory Review Period for Purposes of Patent Extension; CARTIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CARTIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",85 FR 41999,2020-15011,https://www.federalregister.gov/documents/2020/07/13/2020-15011/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cartiva,https://www.govinfo.gov/content/pkg/FR-2020-07-13/pdf/2020-15011.pdf,2020-07-13, CARTIVA,,Nicolas,CARTIVA,5981826,"Cartiva, Inc.",2407.0,1979,428.0,2020-09-11,2016-07-01,2016-07-01,PMA 150017,1429
Determination of Regulatory Review Period for Purposes of Patent Extension; XEPI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XEPI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 41996,2020-15013,https://www.federalregister.gov/documents/2020/07/13/2020-15013/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xepi,https://www.govinfo.gov/content/pkg/FR-2020-07-13/pdf/2020-15013.pdf,2020-07-13, XEPI,,Nicolas,XEPI,6335447,"Toyama Chemical Co., Ltd.",2819.0,2282,537.0,2020-09-11,2010-03-26,2017-12-11,NDA 208945,1678
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",85 FR 42863,2020-15295,https://www.federalregister.gov/documents/2020/07/15/2020-15295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istent-inject-trabecular,https://www.govinfo.gov/content/pkg/FR-2020-07-15/pdf/2020-15295.pdf,2020-07-15, ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,,Nicolas,ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,7867186; 9301875; and 9597230,Glaukos Corporation,2508.0,2330,178.0,2020-09-14,2011-08-11,2018-06-21,PMA 170043,1783
Determination of Regulatory Review Period for Purposes of Patent Extension; OXERVATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXERVATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 51446,2020-18239,https://www.federalregister.gov/documents/2020/08/20/2020-18239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxervate,https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18239.pdf,2020-08-20, OXERVATE,,Nicolas,OXERVATE,8501439,Dompe Farmaceutici S.p.A.,1484.0,1240,244.0,2020-10-19,2014-08-01,2018-08-22,BLA 761094,863
Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYLEESI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 51448,2020-18240,https://www.federalregister.gov/documents/2020/08/20/2020-18240/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyleesi,https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18240.pdf,2020-08-20, VYLEESI,,Nicolas,VYLEESI,6579968 and 6794489,"Palatin Technologies, Inc.",6721.0,6265,456.0,2020-10-19,2001-01-27,2019-06-21,NDA 210557,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; POTELIGEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POTELIGEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 53823,2020-19036,https://www.federalregister.gov/documents/2020/08/31/2020-19036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-poteligeo,https://www.govinfo.gov/content/pkg/FR-2020-08-31/pdf/2020-19036.pdf,2020-08-31, POTELIGEO,,Nicolas,POTELIGEO,6989145 and 7504104,Kyowa Hakko Kirin,3536.0,3227,309.0,2020-10-30,2008-12-04,2018-08-08,BLA 761051,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ELZONRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELZONRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 53824,2020-19085,https://www.federalregister.gov/documents/2020/08/31/2020-19085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elzonris,https://www.govinfo.gov/content/pkg/FR-2020-08-31/pdf/2020-19085.pdf,2020-08-31, ELZONRIS,,Nicolas,ELZONRIS,9181317 and 9631006,Scott & White Memorial Hospital,5541.0,5357,184.0,2020-10-30,2003-10-22,2018-12-21,BLA 761116,394
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMOXITI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMOXITI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",85 FR 54388,2020-19214,https://www.federalregister.gov/documents/2020/09/01/2020-19214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumoxiti,https://www.govinfo.gov/content/pkg/FR-2020-09-01/pdf/2020-19214.pdf,2020-09-01, LUMOXITI,,Nicolas,LUMOXITI,8809502; 9580461; and 10072083,the U.S. Department of Health,4320.0,4092,228.0,2020-11-02,2006-11-17,2018-09-13,BLA 761104,2
Determination of Regulatory Review Period for Purposes of Patent Extension; EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM (EVERSENSE CGM SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",85 FR 56229,2020-20040,https://www.federalregister.gov/documents/2020/09/11/2020-20040/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eversense-continuous,https://www.govinfo.gov/content/pkg/FR-2020-09-11/pdf/2020-20040.pdf,2020-09-11, EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM,,Nicolas,EVERSENSE CGM SYSTEM,6400974,"Senseonics, Inc.",90.0,3727,3123.0,2020-11-10,2020-11-10,2018-06-21,PMA P160048,5
Determination of Regulatory Review Period for Purposes of Patent Extension; TAKHZYRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAKHZYRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 56622,2020-20104,https://www.federalregister.gov/documents/2020/09/14/2020-20104/determination-of-regulatory-review-period-for-purposes-of-patent-extension-takhzyro,https://www.govinfo.gov/content/pkg/FR-2020-09-14/pdf/2020-20104.pdf,2020-09-14, TAKHZYRO,,Nicolas,TAKHZYRO,8816055,Dyax Corp.,1857.0,1616,241.0,2020-11-13,2013-07-25,2018-08-23,BLA 761090,849
Determination of Regulatory Review Period for Purposes of Patent Extension; OCS LUNG SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for OCS LUNG SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 14455,2021-05372,https://www.federalregister.gov/documents/2021/03/16/2021-05372/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocs-lung-system,https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05372.pdf,2021-03-16, OCS LUNG SYSTEM,,Nicolas,OCS LUNG SYSTEM,6100082,"TransMedics, Inc.",2341.0,1672,669.0,2021-09-13,2021-09-13,2018-03-22,PMA P160013,1687
Determination of Regulatory Review Period for Purposes of Patent Extension; HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 14445,2021-05371,https://www.federalregister.gov/documents/2021/03/16/2021-05371/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hintermann-series-h3,https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05371.pdf,2021-03-16, HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,,Nicolas,HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,6409767,European Foot Platform,4676.0,3661,1015.0,2021-09-13,2006-08-17,2019-06-04,PMA 160036,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; BAROSTIM NEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAROSTIM NEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 15950,2021-06210,https://www.federalregister.gov/documents/2021/03/25/2021-06210/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barostim-neo,https://www.govinfo.gov/content/pkg/FR-2021-03-25/pdf/2021-06210.pdf,2021-03-25, BAROSTIM NEO,,Nicolas,BAROSTIM NEO,8606359; 9044609; and 9427583,"CVRx, Inc.",2550.0,2310,240.0,2021-09-21,2021-09-21,2019-08-16,PMA 180050,1038
Determination of Regulatory Review Period for Purposes of Patent Extension; IBSRELA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IBSRELA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17157,2021-06693,https://www.federalregister.gov/documents/2021/04/01/2021-06693/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibsrela,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06693.pdf,2021-04-01, IBSRELA,,Nicolas,IBSRELA,8541448,"Ardelyx, Inc.",3219.0,2853,366.0,2021-09-28,2010-11-21,2019-09-12,NDA 211801,1272
Determination of Regulatory Review Period for Purposes of Patent Extension; TPOXX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for TPOXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17160,2021-06696,https://www.federalregister.gov/documents/2021/04/01/2021-06696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tpoxx,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06696.pdf,2021-04-01, TPOXX,,Nicolas,TPOXX,7737168 and 8124643,"SIGA Technologies, Inc.",4601.0,4383,218.0,2021-09-28,2005-12-09,2018-07-13,NDA 208627,1585
Determination of Regulatory Review Period for Purposes of Patent Extension; BIOMIMICS 3D VASCULAR STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BIOMIMICS 3D VASCULAR STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 17167,2021-06709,https://www.federalregister.gov/documents/2021/04/01/2021-06709/determination-of-regulatory-review-period-for-purposes-of-patent-extension-biomimics-3d-vascular,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06709.pdf,2021-04-01, BIOMIMICS 3D VASCULAR STENT SYSTEM,,Nicolas,BIOMIMICS 3D VASCULAR STENT SYSTEM,9314353,Veryan Medical Limited,1234.0,973,261.0,2021-09-28,2021-09-28,2018-10-04,PMA 180003,580
Determination of Regulatory Review Period for Purposes of Patent Extension; OPTIMIZER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OPTIMIZER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 30957,2021-12192,https://www.federalregister.gov/documents/2021/06/10/2021-12192/determination-of-regulatory-review-period-for-purposes-of-patent-extension-optimizer,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12192.pdf,2021-06-10, OPTIMIZER,,Nicolas,OPTIMIZER,8260416 and 8311629,Impulse Dynamics N.V.,5434.0,5236,198.0,2021-12-07,2004-05-06,2019-03-21,PMA 180036,1293
Determination of Regulatory Review Period for Purposes of Patent Extension; WAKIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for WAKIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30947,2021-12148,https://www.federalregister.gov/documents/2021/06/10/2021-12148/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wakix,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12148.pdf,2021-06-10, WAKIX,,Nicolas,WAKIX,8207197 and 8486947,Bioprojet,505.0,261,244.0,2021-12-07,2018-03-29,2019-08-14,NDA 211150,389
Determination of Regulatory Review Period for Purposes of Patent Extension; SARCLISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SARCLISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30950,2021-12189,https://www.federalregister.gov/documents/2021/06/10/2021-12189/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sarclisa,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12189.pdf,2021-06-10, SARCLISA,,Nicolas,SARCLISA,8153765 and 10342869,SANOFI,3718.0,3410,308.0,2021-12-07,2009-12-29,2020-03-02,BLA 761113,1596
Determination of Regulatory Review Period for Purposes of Patent Extension; SPRAVATO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPRAVATO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30955,2021-12193,https://www.federalregister.gov/documents/2021/06/10/2021-12193/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spravato,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12193.pdf,2021-06-10, SPRAVATO,,Nicolas,SPRAVATO,8785500 and 9592207,"Icahn School of Medicine at Mt. Sinai, Yale University",2456.0,2273,183.0,2021-12-07,2012-06-15,2019-03-05,NDA 211243,596
Determination of Regulatory Review Period for Purposes of Patent Extension; EVENITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVENITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30942,2021-12199,https://www.federalregister.gov/documents/2021/06/10/2021-12199/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evenity,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12199.pdf,2021-06-10, EVENITY,,Nicolas,EVENITY,7592429; 8017120; and 8440193,Amgen Inc.,4519.0,3524,995.0,2021-12-07,2006-11-26,2019-04-09,BLA 761062,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; XPOVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XPOVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30945,2021-12167,https://www.federalregister.gov/documents/2021/06/10/2021-12167/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xpovio,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12167.pdf,2021-06-10, XPOVIO,,Nicolas,XPOVIO,8999996,Karyopharm Therapeutics Inc.,2585.0,2253,332.0,2021-12-07,2012-06-06,2019-07-03,NDA 212306,291
Determination of Regulatory Review Period for Purposes of Patent Extension; MAYZENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAYZENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30949,2021-12171,https://www.federalregister.gov/documents/2021/06/10/2021-12171/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mayzent,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12171.pdf,2021-06-10, MAYZENT,,Nicolas,MAYZENT,7939519 and 8492441,Novartis AG,4544.0,4299,245.0,2021-12-07,2006-10-19,2019-03-26,NDA 209884,848
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) published a notice in the Federal Register of February 12, 2018. After review of a timely request for reconsideration by the applicant of the determination of the regulatory review period of the animal drug, BRAVECTO, in that notice, FDA has determined that a revision of the SUPPLEMENTARY INFORMATION section is warranted. This document presents the revised regulatory review period.",86 FR 31318,2021-12284,https://www.federalregister.gov/documents/2021/06/11/2021-12284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto-correction,https://www.govinfo.gov/content/pkg/FR-2021-06-11/pdf/2021-12284.pdf,2021-06-11, BRAVECTO, Correction,Nicolas,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GIVLAARI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GIVLAARI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 32936,2021-13176,https://www.federalregister.gov/documents/2021/06/23/2021-13176/determination-of-regulatory-review-period-for-purposes-of-patent-extension-givlaari,https://www.govinfo.gov/content/pkg/FR-2021-06-23/pdf/2021-13176.pdf,2021-06-23, GIVLAARI,,Nicolas,GIVLAARI,9133461,"Alnylam Pharmaceuticals, Inc.",1533.0,1363,170.0,2021-12-20,2015-09-11,2019-11-20,NDA 212194,190
Determination of Regulatory Review Period for Purposes of Patent Extension; TURALIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TURALIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 32950,2021-13186,https://www.federalregister.gov/documents/2021/06/23/2021-13186/determination-of-regulatory-review-period-for-purposes-of-patent-extension-turalio,https://www.govinfo.gov/content/pkg/FR-2021-06-23/pdf/2021-13186.pdf,2021-06-23, TURALIO,,Nicolas,TURALIO,7893075; 8461169; and 9169250,Plexxikon Inc.,3637.0,3394,243.0,2021-12-20,2009-08-19,2019-08-02,NDA 211810,810
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOLGENSMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZOLGENSMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 33307,2021-13411,https://www.federalregister.gov/documents/2021/06/24/2021-13411/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zolgensma,https://www.govinfo.gov/content/pkg/FR-2021-06-24/pdf/2021-13411.pdf,2021-06-24, ZOLGENSMA,,Nicolas,ZOLGENSMA,7906111,"REGENXBIO, Inc.",2088.0,1852,236.0,2021-12-21,2013-09-06,2019-05-24,BLA 125694,1162
Determination of Regulatory Review Period for Purposes of Patent Extension; TAZVERIK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAZVERIK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34022,2021-13743,https://www.federalregister.gov/documents/2021/06/28/2021-13743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tazverik,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13743.pdf,2021-06-28, TAZVERIK,,Nicolas,TAZVERIK,8410088,"Epizyme, Inc.",1618.0,1372,246.0,2021-12-27,2015-08-21,2020-01-23,NDA 211723,650
Determination of Regulatory Review Period for Purposes of Patent Extension; GORE CARDIOFORM ASD OCCLUDER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for GORE CARDIOFORM ASD OCCLUDER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 34023,2021-13687,https://www.federalregister.gov/documents/2021/06/28/2021-13687/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gore-cardioform-asd,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13687.pdf,2021-06-28, GORE CARDIOFORM ASD OCCLUDER,,Nicolas,GORE CARDIOFORM ASD OCCLUDER,9474517,"W.L. Gore & Associates, Inc.",931.0,751,556.0,2021-12-27,2016-11-10,2019-05-28,PMA 050006,556
"Determination of Regulatory Review Period for Purposes of Patent Extension; Smallpox and Monkeypox Vaccine, Live",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Smallpox and Monkeypox Vaccine, Live and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 34018,2021-13686,https://www.federalregister.gov/documents/2021/06/28/2021-13686/determination-of-regulatory-review-period-for-purposes-of-patent-extension-smallpox-and-monkeypox,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13686.pdf,2021-06-28," Smallpox and Monkeypox Vaccine, Live",,Nicolas,"Smallpox and Monkeypox Vaccine, Live",7335364,Bavarian Nordic A/S,5650.0,5315,335.0,2021-12-27,2004-04-07,2019-09-24,BLA 125678,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; OXBRYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXBRYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34767,2021-13976,https://www.federalregister.gov/documents/2021/06/30/2021-13976/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxbryta,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13976.pdf,2021-06-30, OXBRYTA,,Nicolas,OXBRYTA,9018210 10017491 and 10034879,"Global Blood Therapeutics, Inc.",1847.0,1694,153.0,2021-12-27,2014-11-06,2019-11-25,NDA 213137,332
Determination of Regulatory Review Period for Purposes of Patent Extension; FETROJA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FETROJA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34762,2021-13971,https://www.federalregister.gov/documents/2021/06/30/2021-13971/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fetroja,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13971.pdf,2021-06-30, FETROJA,,Nicolas,FETROJA,9238657,"Shionogi & Co., Ltd.",2400.0,2064,336.0,2021-12-27,2013-04-21,2019-11-14,NDA 209445,726
Determination of Regulatory Review Period for Purposes of Patent Extension; BALVERSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BALVERSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34764,2021-13973,https://www.federalregister.gov/documents/2021/06/30/2021-13973/determination-of-regulatory-review-period-for-purposes-of-patent-extension-balversa,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13973.pdf,2021-06-30, BALVERSA,,Nicolas,BALVERSA,8895601,Astex Therapeutics Ltd.,2179.0,1972,207.0,2021-12-27,2013-04-26,2019-04-12,NDA 212018,691
Determination of Regulatory Review Period for Purposes of Patent Extension; POLIVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POLIVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",86 FR 34768,2021-13949,https://www.federalregister.gov/documents/2021/06/30/2021-13949/determination-of-regulatory-review-period-for-purposes-of-patent-extension-polivy,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13949.pdf,2021-06-30, POLIVY,,Nicolas,POLIVY,8088378; 8545850; and 8691531,"Genentech, Inc.",3050.0,2876,174.0,2021-12-27,2011-02-04,2019-06-10,BLA 761121,1445
Determination of Regulatory Review Period for Purposes of Patent Extension; AXONICS SACRAL NEUROMODULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AXONICS SACRAL NEUROMODULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 34757,2021-13972,https://www.federalregister.gov/documents/2021/06/30/2021-13972/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axonics-sacral,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13972.pdf,2021-06-30, AXONICS SACRAL NEUROMODULATION SYSTEM,,Nicolas,AXONICS SACRAL NEUROMODULATION SYSTEM,7331499,Alfred E. Mann Foundation for Scientific[[Page 34759]]Research,681.0,494,187.0,2021-12-27,2017-10-27,2019-09-06,PMA 190006,434
Determination of Regulatory Review Period for Purposes of Patent Extension; BARHEMSYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BARHEMSYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 35803,2021-14461,https://www.federalregister.gov/documents/2021/07/07/2021-14461/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barhemsys,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14461.pdf,2021-07-07, BARHEMSYS,,Nicolas,BARHEMSYS,9084765,Acacia Pharma Limited,2960.0,2085,875.0,2022-01-03,2012-01-21,2020-02-26,NDA 209510,1085
Determination of Regulatory Review Period for Purposes of Patent Extension; BEOVU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEOVU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 35805,2021-14473,https://www.federalregister.gov/documents/2021/07/07/2021-14473/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beovu,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14473.pdf,2021-07-07, BEOVU,,Nicolas,BEOVU,8349322 and 9090684,Novartis AG,3064.0,2821,243.0,2022-01-03,2011-05-20,2019-10-07,BLA 761125,1354
Determination of Regulatory Review Period for Purposes of Patent Extension; Zephyr Endobronchial Valve Implant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zephyr Endobronchial Valve Implant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 35807,2021-14482,https://www.federalregister.gov/documents/2021/07/07/2021-14482/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zephyr-endobronchial,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14482.pdf,2021-07-07, Zephyr Endobronchial Valve Implant,,Nicolas,ZEPHYR ENDOBRONCHIAL VALVE IMPLANT,6527761 and 7798147,Pulmonx Corp.,5744.0,5565,179.0,2022-01-03,2022-01-03,2018-06-29,PMA 180002,1510
Determination of Regulatory Review Period for Purposes of Patent Extension; PIQRAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIQRAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 36142,2021-14490,https://www.federalregister.gov/documents/2021/07/08/2021-14490/determination-of-regulatory-review-period-for-purposes-of-patent-extension-piqray,https://www.govinfo.gov/content/pkg/FR-2021-07-08/pdf/2021-14490.pdf,2021-07-08, PIQRAY,,Nicolas,PIQRAY,8277462 and 8476268,Novartis AG,3264.0,3106,158.0,2022-01-04,2010-06-18,2019-05-24,NDA 212526,1156
Determination of Regulatory Review Period for Purposes of Patent Extension; AJOVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AJOVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 36285,2021-14652,https://www.federalregister.gov/documents/2021/07/09/2021-14652/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ajovy,https://www.govinfo.gov/content/pkg/FR-2021-07-09/pdf/2021-14652.pdf,2021-07-09, AJOVY,,Nicolas,AJOVY,8007794,Teva Pharmaceuticals International GmbH,3216.0,2882,334.0,2022-01-05,2009-11-26,2018-09-14,BLA 761089,1454
Determination of Regulatory Review Period for Purposes of Patent Extension; NUBEQA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NUBEQA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 58670,2021-23074,https://www.federalregister.gov/documents/2021/10/22/2021-23074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nubeqa,https://www.govinfo.gov/content/pkg/FR-2021-10-22/pdf/2021-23074.pdf,2021-10-22, NUBEQA,,Nicolas,NUBEQA,8975254,Orion Corporation,2576.0,2420,156.0,2022-04-20,2012-07-13,2019-07-30,NDA 212099,879
Determination of Regulatory Review Period for Purposes of Patent Extension; INREBIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INREBIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59397,2021-23388,https://www.federalregister.gov/documents/2021/10/27/2021-23388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inrebic,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23388.pdf,2021-10-27, INREBIC,,Nicolas,INREBIC,7528143; 7825246; and 8138199,"Impact Biomedicines, Inc.",4285.0,4059,226.0,2022-04-25,2007-11-24,2019-08-16,NDA 212327,1796
Determination of Regulatory Review Period for Purposes of Patent Extension; XENLETA Tablets New Drug Application 211672,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENLETA tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59392,2021-23387,https://www.federalregister.gov/documents/2021/10/27/2021-23387/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenleta-tablets-new-drug,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23387.pdf,2021-10-27, XENLETA Tablets New Drug Application 211672,,Nicolas,XENLETA tablets,8071643; 8153689; and 9120727,Nabriva Therapeutics GMBH,3595.0,3351,244.0,2022-04-25,2020-10-13,2019-08-19,NDA 211672,1528
Determination of Regulatory Review Period for Purposes of Patent Extension; XENLETA Injection New Drug Application 211673,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENLETA injection new drug application (NDA) 211673 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59394,2021-23386,https://www.federalregister.gov/documents/2021/10/27/2021-23386/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenleta-injection-new,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23386.pdf,2021-10-27, XENLETA Injection New Drug Application 211673,,Nicolas,XENLETA injection,8071643 and 8153689,Nabriva Therapeutics GMBH,3595.0,3351,244.0,2022-04-25,2021-12-27,2019-08-19,NDA 211673,1528
Determination of Regulatory Review Period for Purposes of Patent Extension; SPINRAZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPINRAZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",86 FR 60248,2021-23719,https://www.federalregister.gov/documents/2021/11/01/2021-23719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spinraza,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23719.pdf,2021-11-01, SPINRAZA,,Nicolas,SPINRAZA,"U.S. Patent Nos. 7,838,657 and 8,110,560 from University of Massachusetts, and U.S. Patent Nos. 8,361,977 and 8,980,853 from Biogen MA Inc., and Cold Spring Harbor Laboratory","University of Massachusetts and Biogen MA Inc., and Cold Spring Harbor Laboratory",1891.0,1799,92.0,2011-10-22,2011-10-22,2016-12-23,NDA 209531,992
Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENHERTU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60252,2021-23725,https://www.federalregister.gov/documents/2021/11/01/2021-23725/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23725.pdf,2021-11-01, ENHERTU,,Nicolas,ENHERTU,9808537; 10155821; and 10195288,"Daiichi Sankyo Company, Limited",1395.0,186,1209.0,2016-02-26,2016-02-26,2019-12-20,BLA 761139,71
Determination of Regulatory Review Period for Purposes of Patent Extension; VYONDYS 53,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYONDYS 53 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60256,2021-23724,https://www.federalregister.gov/documents/2021/11/01/2021-23724/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyondys-53,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23724.pdf,2021-11-01, VYONDYS 53,,Nicolas,VYONDYS 53,9024007; 9994851; 10227590; 10266827; 10421966; and RE47691,The University of Western Australia,1833.0,1474,359.0,2014-12-07,2014-12-07,2019-12-12,NDA 211970,888
Determination of Regulatory Review Period for Purposes of Patent Extension; ADAKVEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADAKVEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60829,2021-24070,https://www.federalregister.gov/documents/2021/11/04/2021-24070/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adakveo,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24070.pdf,2021-11-04, ADAKVEO,,Nicolas,ADAKVEO,8377440 and 9556266,Novartis AG,3152.0,2968,184.0,2011-04-01,2011-04-01,2019-11-15,BLA 761128,601
Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCENESSE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60832,2021-24074,https://www.federalregister.gov/documents/2021/11/04/2021-24074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-scenesse,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24074.pdf,2021-11-04, SCENESSE,,Nicolas,SCENESSE,8334265,Clinuvel Pharmaceuticals Limited,3914.0,3579,335.0,2009-01-21,2009-01-21,2019-10-08,NDA 210797,1481
Determination of Regulatory Review Period for Purposes of Patent Extension; SEVENFACT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEVENFACT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60827,2021-24065,https://www.federalregister.gov/documents/2021/11/04/2021-24065/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sevenfact,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24065.pdf,2021-11-04, SEVENFACT,,Nicolas,SEVENFACT,9029316,Laboratoire Francais du Fractionnement et des Biotechnologies S.A. (LFB S.A.),2785.0,1518,1267.0,2012-08-18,2012-08-18,2020-04-01,BLA 125641,482
Determination of Regulatory Review Period for Purposes of Patent Extension; AKLIEF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AKLIEF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60831,2021-24077,https://www.federalregister.gov/documents/2021/11/04/2021-24077/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aklief,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24077.pdf,2021-11-04, AKLIEF,,Nicolas,AKLIEF,7807708; 8227507; and 8470871,Galderma Research & Development,3137.0,2771,366.0,2011-03-05,2011-03-05,2019-10-04,NDA 211527,1329
Determination of Regulatory Review Period for Purposes of Patent Extension; DENGVAXIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DENGVAXIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60835,2021-24067,https://www.federalregister.gov/documents/2021/11/04/2021-24067/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dengvaxia,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24067.pdf,2021-11-04, DENGVAXIA,,Nicolas,DENGVAXIA,8142795,Sanofi Pasteur,5710.0,5466,244.0,2003-09-14,2003-09-14,2019-05-01,BLA 125682,1248
Determination of Regulatory Review Period for Purposes of Patent Extension; RECARBRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECARBRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60837,2021-24068,https://www.federalregister.gov/documents/2021/11/04/2021-24068/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recarbrio,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24068.pdf,2021-11-04, RECARBRIO,,Nicolas,RECARBRIO,8487093,Merck Sharp & Dohme Corp.,3200.0,2957,243.0,2010-10-13,2010-10-13,2019-07-16,NDA 212819,1218
Determination of Regulatory Review Period for Purposes of Patent Extension; DOJOLVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DOJOLVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",86 FR 62181,2021-24435,https://www.federalregister.gov/documents/2021/11/09/2021-24435/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dojolvi,https://www.govinfo.gov/content/pkg/FR-2021-11-09/pdf/2021-24435.pdf,2021-11-09, DOJOLVI,,Nicolas,DOJOLVI,8697748 and 9186344,Ultragenyx Pharmaceutical Inc.,2511.0,2175,336.0,2013-08-17,2013-08-17,2020-06-30,NDA 213687,1303
Determination of Regulatory Review Period for Purposes of Patent Extension; QINLOCK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QINLOCK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 63402,2021-24978,https://www.federalregister.gov/documents/2021/11/16/2021-24978/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qinlock,https://www.govinfo.gov/content/pkg/FR-2021-11-16/pdf/2021-24978.pdf,2021-11-16, QINLOCK,,Nicolas,QINLOCK,8188113 and 8461179,Deciphera Pharmaceuticals LLC,1741.0,1586,155.0,2015-08-11,2015-08-11,2020-05-15,NDA 213973,947
Determination of Regulatory Review Period for Purposes of Patent Extension; SUNOSI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SUNOSI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 64947,2021-25297,https://www.federalregister.gov/documents/2021/11/19/2021-25297/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sunosi,https://www.govinfo.gov/content/pkg/FR-2021-11-19/pdf/2021-25297.pdf,2021-11-19, SUNOSI,,Nicolas,SUNOSI,8440715,"JAZZ Pharmaceutials, Inc.",8209.0,7664,545.0,1996-12-27,1996-12-27,2019-06-17,IND 52082,1386
Determination of Regulatory Review Period for Purposes of Patent Extension; TRODELVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRODELVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 67065,2021-25612,https://www.federalregister.gov/documents/2021/11/24/2021-25612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trodelvy,https://www.govinfo.gov/content/pkg/FR-2021-11-24/pdf/2021-25612.pdf,2021-11-24, TRODELVY,,Nicolas,TRODELVY,7999083,"Immunomedics, Inc.",2856.0,2150,706.0,2012-06-29,2012-06-29,2020-04-22,BLA 761115,1780
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEPZELCA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEPZELCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 67960,2021-26009,https://www.federalregister.gov/documents/2021/11/30/2021-26009/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zepzelca,https://www.govinfo.gov/content/pkg/FR-2021-11-30/pdf/2021-26009.pdf,2021-11-30, ZEPZELCA,,Nicolas,ZEPZELCA,7763615,"Pharma Mar, S.A.",4170.0,3987,183.0,2009-01-16,2009-01-16,2020-06-15,NDA 213702,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of November 1, 2021, for the determination of a regulatory review period for purposes of patent extension for the human biological product, ENHERTU. This document corrects that notice by adjusting the applicable regulatory review period for the testing phase and approval phase of the product, ENHERTU.",87 FR 1762,2022-00404,https://www.federalregister.gov/documents/2022/01/12/2022-00404/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu-correction,https://www.govinfo.gov/content/pkg/FR-2022-01-12/pdf/2022-00404.pdf,2022-01-12, ENHERTU, Correction,Nicolas,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DANYELZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DANYELZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 38761,2022-13860,https://www.federalregister.gov/documents/2022/06/29/2022-13860/determination-of-regulatory-review-period-for-purposes-of-patent-extension-danyelza,https://www.govinfo.gov/content/pkg/FR-2022-06-29/pdf/2022-13860.pdf,2022-06-29, DANYELZA,,Nicolas,DANYELZA,9315585,Memorial Sloan Kettering Cancer Center,3423.0,3183,240.0,2011-07-15,2011-07-15,2020-11-25,BLA 761171,3421
Determination of Regulatory Review Period for Purposes of Patent Extension; RUKOBIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUKOBIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 38763,2022-13856,https://www.federalregister.gov/documents/2022/06/29/2022-13856/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rukobia,https://www.govinfo.gov/content/pkg/FR-2022-06-29/pdf/2022-13856.pdf,2022-06-29, RUKOBIA,,Nicolas,RUKOBIA,8168615,ViiV Healthcare UK,5322.0,5110,212.0,2005-12-08,2005-12-08,2020-07-02,NDA 212950,1597
Determination of Regulatory Review Period for Purposes of Patent Extension; TEPEZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEPEZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 39099,2022-13956,https://www.federalregister.gov/documents/2022/06/30/2022-13956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tepezza,https://www.govinfo.gov/content/pkg/FR-2022-06-30/pdf/2022-13956.pdf,2022-06-30, TEPEZZA,,Nicolas,TEPEZZA,7572897,Hoffman-La Roche Inc.,2958.0,2760,198.0,2011-12-18,2011-12-18,2020-01-21,BLA 761143,1578
Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMCIVREE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 39531,2022-14134,https://www.federalregister.gov/documents/2022/07/01/2022-14134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imcivree,https://www.govinfo.gov/content/pkg/FR-2022-07-01/pdf/2022-14134.pdf,2022-07-01, IMCIVREE,,Nicolas,IMCIVREE,8039435; 9458195,"RHYTHM PHARMACEUTICALS, INC.",3304.0,3060,244.0,2011-11-11,2011-11-11,2020-11-25,NDA 213793,1774
Determination of Regulatory Review Period for Purposes of Patent Extension; VYEPTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYEPTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40248,2022-14350,https://www.federalregister.gov/documents/2022/07/06/2022-14350/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyepti,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14350.pdf,2022-07-06, VYEPTI,,Nicolas,VYEPTI,9745373,AlderBio Holdings LLC,2599.0,2233,366.0,2013-01-11,2013-01-11,2020-02-21,BLA 761119,637
Determination of Regulatory Review Period for Purposes of Patent Extension; MONJUVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONJUVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40251,2022-14357,https://www.federalregister.gov/documents/2022/07/06/2022-14357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monjuvi,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14357.pdf,2022-07-06, MONJUVI,,Nicolas,MONJUVI,8524867; 9803020,"Xenocor, Inc.",3806.0,3590,216.0,2010-03-03,2010-03-03,2020-07-31,BLA 761163,1370
Determination of Regulatory Review Period for Purposes of Patent Extension; MARGENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MARGENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40256,2022-14360,https://www.federalregister.gov/documents/2022/07/06/2022-14360/determination-of-regulatory-review-period-for-purposes-of-patent-extension-margenza,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14360.pdf,2022-07-06, MARGENZA,,Nicolas,MARGENZA,8802093,"MacroGenics, Inc.",3950.0,3585,365.0,2010-02-24,2010-02-24,2020-12-16,BLA 761150,1342
Determination of Regulatory Review Period for Purposes of Patent Extension; XEGLYZE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XEGLYZE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 40534,2022-14430,https://www.federalregister.gov/documents/2022/07/07/2022-14430/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xeglyze,https://www.govinfo.gov/content/pkg/FR-2022-07-07/pdf/2022-14430.pdf,2022-07-07, XEGLYZE,,Nicolas,XEGLYZE,7812163; 8212038,"Dr. Reddy's Laboratories, S.A.",4573.0,2797,1776.0,2008-01-18,2008-01-18,2020-07-24,NDA 206966,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; RINVOQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RINVOQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",87 FR 40536,2022-14431,https://www.federalregister.gov/documents/2022/07/07/2022-14431/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rinvoq,https://www.govinfo.gov/content/pkg/FR-2022-07-07/pdf/2022-14431.pdf,2022-07-07, RINVOQ,,Nicolas,RINVOQ,8962629; RE47221,AbbVie,2604.0,2365,239.0,2012-07-01,2012-07-01,2019-08-16,NDA 211675,989
Determination of Regulatory Review Period for Purposes of Patent Extension; UPLIZNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UPLIZNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40851,2022-14539,https://www.federalregister.gov/documents/2022/07/08/2022-14539/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uplizna,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14539.pdf,2022-07-08, UPLIZNA,,Nicolas,UPLIZNA,8323653,"Viela Bio, Inc.",4033.0,3666,367.0,2009-05-29,2009-05-29,2020-06-11,BLA 761142,1557
Determination of Regulatory Review Period for Purposes of Patent Extension; PADCEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PADCEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40847,2022-14548,https://www.federalregister.gov/documents/2022/07/08/2022-14548/determination-of-regulatory-review-period-for-purposes-of-patent-extension-padcev,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14548.pdf,2022-07-08, PADCEV,,Nicolas,PADCEV,9078931; 9314538; 9962454; RE48389 (previously U.S. Patent No. 8637642),"AGENSYS, Inc.",2546.0,2389,157.0,2012-12-30,2012-12-30,2019-12-18,BLA 761137,811
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROZLYTREK INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 40849,2022-14546,https://www.federalregister.gov/documents/2022/07/08/2022-14546/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-injection,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14546.pdf,2022-07-08, ROZLYTREK INJECTION,,Nicolas,ROZLYTREK INJECTION,8299057; 8673893; 9029356; and 9085565,"Genentech, Inc.",1968.0,1727,241.0,2014-03-28,2014-03-28,2019-08-15,NDA 212726,1104
Determination of Regulatory Review Period for Purposes of Patent Extension; TABRECTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TABRECTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 41133,2022-14674,https://www.federalregister.gov/documents/2022/07/11/2022-14674/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tabrecta,https://www.govinfo.gov/content/pkg/FR-2022-07-11/pdf/2022-14674.pdf,2022-07-11, TABRECTA,,Nicolas,TABRECTA,7767675; 8420645,Incyte Corp.,4164.0,4015,149.0,2008-12-13,2008-12-13,2020-05-06,NDA 213591,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENSPRYNG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",87 FR 41724,2022-14930,https://www.federalregister.gov/documents/2022/07/13/2022-14930/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enspryng,https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14930.pdf,2022-07-13, ENSPRYNG,,Nicolas,ENSPRYNG,8562991; 10022319; 10662245,"Genentech, Inc.",2495.0,2128,367.0,2013-10-18,2013-10-18,2020-08-14,BLA 761149,1428
Determination of Regulatory Review Period for Purposes of Patent Extension; BLENREP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLENREP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 41727,2022-14916,https://www.federalregister.gov/documents/2022/07/13/2022-14916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blenrep,https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14916.pdf,2022-07-13, BLENREP,,Nicolas,BLENREP,9273141,Glaxo Group Ltd,2352.0,2107,245.0,2014-02-28,2014-02-28,2020-08-05,BLA 761158,803
Determination of Regulatory Review Period for Purposes of Patent Extension; TAUVID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAUVID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 43874,2022-15679,https://www.federalregister.gov/documents/2022/07/22/2022-15679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tauvid,https://www.govinfo.gov/content/pkg/FR-2022-07-22/pdf/2022-15679.pdf,2022-07-22, TAUVID,,Nicolas,TAUVID,8932557,Eli Lilly,3067.0,2825,242.0,2012-01-06,2012-01-06,2020-05-28,NDA 212123,1102
